If authorised, Vimkunya would be the first vaccine in the EU to protect adolescents aged 12 to 17 against Chikungunya.

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Ugandan health officials on Thursday confirmed a case of Ebola in the capital Kampala, in a nurse who sought care at a number ...